Skip to main content
ELAB
NASDAQ Life Sciences

Consultant receives options for 7.4% stake in PMGC Holdings

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
8
Price
$1.81
Mkt Cap
$8.224M
52W Low
$1.62
52W High
$309.12
Market data snapshot near publication time

Summary

A consultant to PMGC Holdings Inc. received options for 450,277 shares, increasing their beneficial ownership to 7.40% of the company.


Key Events

  • Significant Option Grant

    Braeden Lichti, through Northstrive Companies Inc., was granted options for 450,277 shares of common stock on June 1, 2026.

  • Purpose of Grant

    The options were issued as partial consideration for consultant services provided to PMGC Holdings Inc.

  • Increased Beneficial Ownership

    Following the grant, Braeden Lichti and Northstrive Companies Inc. now beneficially own 450,313 shares, representing 7.40% of the company's outstanding common stock on a post-reverse split basis.

  • Context of Dilution

    This substantial equity grant adds to the company's recent pattern of significant share issuances and dilution, occurring amidst a 'going concern' warning and active capital raising efforts.


Analysis

This amendment to a Schedule 13D reveals that Braeden Lichti, through his wholly-owned entity Northstrive Companies Inc., was granted options for 450,277 shares on June 1, 2026. These options were partial consideration for consultant services. This grant significantly increases the beneficial ownership of the reporting persons to 7.40% of the company's outstanding shares. For a company with a recent 'going concern' warning and a history of substantial dilutive financing, such a large equity grant, representing a significant portion of the company's market value, is a material event that adds to the ongoing dilution for existing shareholders.

At the time of this filing, ELAB was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $1.62 to $309.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELAB - Latest Insights

ELAB
Jun 03, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
ELAB
Jun 03, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
ELAB
Jun 01, 2026, 7:35 AM EDT
Source: Reuters
Importance Score:
8
ELAB
May 15, 2026, 6:11 AM EDT
Source: Wiseek News
Importance Score:
8
ELAB
May 14, 2026, 7:44 PM EDT
Filing Type: DEF 14A
Importance Score:
9
ELAB
May 14, 2026, 6:52 PM EDT
Filing Type: 10-Q
Importance Score:
9
ELAB
May 13, 2026, 6:05 AM EDT
Filing Type: 8-K
Importance Score:
9
ELAB
May 13, 2026, 4:03 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
ELAB
May 04, 2026, 5:14 PM EDT
Filing Type: PRE 14A
Importance Score:
8
ELAB
Apr 28, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
7